All posts by medical

Grey’s Anatomy Round Table: Levi Owns the Hour! – TV Fanatic

It was another one of those bottle episodes when Grey's Anatomy Season 16 Episode 12gave us insight on Levi and his background and family.

The hour also led to the dissolution of Catherine and Richard's marriage.

Join TV Fanatics Meaghan Frey,Paul Dailly, Jasmine Blu, and Grey's Fanatic Berea Orange as they discuss the hour.

Do you like these bottle episodes where they focus on a select few characters?

Meaghan: I don't hate them, but they usually aren't my favorite.

Levi's storyline surrounding his uncle Saul's death was touching and exactly what he needed. It made me so much more invested in his character.

The Webber-Fox dinner, while entertaining, was far too much time spent with Catherine.

Paul: They're hit or miss episodes. I enjoy some of them, but others feel like they don't belong in the narrative.

Berea: I usually always enjoy bottle episodes where we get to delve further into certain characters and their backstories. Learning more about Levi was good, and the family dinner was extremely entertaining.

Jasmine: They can be hit or miss for me. I liked half of this one and was uninterested in the other half.

What were your thoughts on Levi's storyline involving the death of his uncle Saul?

Meaghan: I loved it! Levi thinking he killed Saul with his confession was equal parts hilarious and heartbreaking.

I killed him with my gayness.

The fact that Saul knew all along that Levi is gay, but never pushed him to talk about it shows just how much he loved and accepted him.

I am also so proud that it gave him the courage to stand up for himself and for the acceptance he deserves from his mom.

Paul: It was intriguing, and giving backstory to one of the better characters on the show was needed. Grey's Anatomy excels in character development, and I could watch more episodes about Levi's past.

Berea: Levi is very sweet, and so was this story. It was so nice knowing his Uncle Saul showed him favoritism because he knew him better than he knew himself at the time.

Jasmine: I love Levi, and his portion of the hour was my favorite. I kind of wish the entire episode was just about him and his family, he could have carried it just fine.

I loved that the show explored his faith in addition to showing how far he has come in embracing who he is. I was proud of Levi, and I loved Daniel.

Did you feel Mrs. Schmitt's homophobia came out of nowhere or do you think they covered it well?

Meaghan: It did come out of nowhere in some senses, but I think it was handled well. Not all homophobia is in your face and loud. Some of it is more quiet, like not accepting your son's sexuality enough to tell your family about it, or making your brother feel as if he needed to hide his sexuality his whole life.

Paul: I agree with Meaghan here. It felt thrown in to amp up the conflict and didn't actually serve the story well.

Berea: I actually feel like this was just another contrived storyline (as has become the norm for this season). It was an interesting story, but I dont remember this ever being discussed before now, so it seemed to have come out of nowhere.

When he introduced Nico to his mom as his boyfriend last season, I was under the impression that she accepted it.

Jasmine: I think the issue is how they eased it in. Because there were at least two instances where Levi was shown having tense conversations with his mom on the phone and speaking about her behavior, but they weren't memorable scenes.

They were so small and blink and you miss them type of scenes, and since those were the only breadcrumbs we had to go on, it does feel like it came out of nowhere.

Mrs. Schmitt: One day with Saul and you're super Jewish? Levi: No, but I am super gay.

So I can understand the confusion or annoyance with that, but aside from it, I was proud of Levi for how he approached it, and I did appreciate that if they had to go in that direction, they showed how subtle homophobia can appear because it isn't always the extreme type.

What are your thoughts on the "anniversary" dinner?

Meaghan: It felt a bit forced to me. I understand that they felt like Maggie and Jackson deserved an explanation, but they know the two of them aren't on good terms, and they thought the best way to deliver that type of news was together?

Also, while Vic's set up came from a good place, it was bizarre that she would think it is okay to try to fix up your boyfriend's ex-girlfriend without her permission, and bring that date to an event he wasn't invited to.

Paul: While I agree that it felt forced, it was bursting at the seams with drama. Grey's knows how to do dinner parties, and this was a great way to get the wheels moving on some of the storylines that had stalled.

Berea: This dinner was a hot mess, and I enjoyed every second of it. The shade being thrown by everyone was too funny. I was cracking up at every turn.

First, I would like to say I dont appreciate how theyve dumbed down Vics character for this storyline. How tacky are you as a plus one to invite another plus one to a dinner party?

Maggie: I thought we were celebrating. I brought chocolates. Richard: At least you didn't bring a date.

Jackson was out of line, too, for inviting her (making Maggie a 5th wheel) and not even telling his mother. Theyve made Vic extremely insecure to where she takes it upon herself to try and set Dean up with Maggie.

How she thought that was her place is a mystery to me. The entire dinner you see Maggie and Jackson bickering back and forth (obviously still into each other), and shes just smiling there like an idiot.

He wasnt even going to let her sit next to him at first (Oh my mom usually sits here), meanwhile Maggie was already seated on the other side of him.

I liked her character on the first two seasons of Station 19, but they are ruining her for the sake of this intershow romance drama.

This episode would have been the perfect opportunity for Vic to tell Jackson:

Hey, Ryans funeral [on Station 19 Season 3 Episode 3] made me realize Im still reeling from Ripleys death. And tonight has made it very clear youre not over your ex, so I think we should end this.

But of course, they want to continue this intershow romance for the sake of having some drama.

Additionally, the Catherine/Richard drama is ridiculous. He is being a petulant child. He took it upon himself to protect Meredith (once again) doing something both stupid and illegal. Bailey was completely in her right to fire all three of them.

Catherine: Richard, I am sorry but, Richard: Apologies don't have the word "but" after them. I'm sorry "But." I'm sorry, it's too late.

For him to be holding a grudge because she didnt support him is a joke.

Catherine herself has told Jackson before that nepotism is for the weak. Why would she go out of her way to stop Bailey firing him?

He didnt for a second think about how his actions would reflect on her in the first place. He is too old not to understand that actions have consequences.

The two of them and their lack of communication is mind-blowing. They need to just go to counseling and talk through this foolishness.

And this notion that Catherine would buy Pac North just to close it down is petty and out of character. But then again, she wouldnt be the first one out of character this season.

Jasmine: I thought it was mildly entertaining at times but mostly dumb AF. I didn't understand why they needed to have a formal dinner to announce their separation when all of them have been out of the loop with one another for ages.

Jackson inviting his new girlfriend to a family dinner without telling anyone was ignorant, and how does a plus one invite a plus one? I do agree that Vic is so out of character throughout all of this. It's maddening.

Dean was the saving grace of the dinner party.

Should Maggie work at Pac-North?

Meaghan: I think it is going to be triggering for her, but she will get past it eventually.

I am so confused why the writers would move yet another character over to Pac-North, where Alex is in charge when they don't have Justin Chambers anymore. His absence is going to be even more glaring the longer we spend at Pac-North.

Maggie: Um, Alex thinks I'm worth this much? Richard: Not just Alex, Maggie. Maggie: Then I guess I have a new job.

Paul: I'm on the fence. She will miss out on seeing a lot of her friends and family, but this could be a big opportunity for her, even if she sticks it out for a year. The experience will be valuable.

Berea: Eh. If Alex was still at Pac-North, and we got to see him and Maggie working together, I would be looking forward to it. But knowing thats not happening is not making me excited about it.

However, she should go ahead and take the offer since Tom wants to play games and not give her her job back at Grey-Sloan (which is another thing I take issue with). Maggie better get her job back as Chief of Cardio and NOT working under Teddy.

Jasmine: Meh. Why not?

I would've enjoyed it more if Alex was still there because of how close they used to be, and I'm assuming this was done before the abrupt departure, so there's that. Maybe she needs the break.

Her sisters are preoccupied with their lives to pay attention to what's happening in hers, and maybe a new place will do her some good.

Richard called it quits with Catherine and now she's buying Pac-North in retaliation. React.

Meaghan: Wow, that woman is a piece of work. That was such a spoiled brat move and yet so Catherine. Who buys a whole hospital just to get back at their estranged husband?

It is amazing that Jackson turned out as good as he did with Catherine raising him. I really wish they would just write her off the show. With such a huge cast, there is no room for someone as loathsome as her.

Paul: Catherine has been a frustrating character for some time now. She likes to control people, and I love that Richard is finally snapping back at her. Catherine does not love Richard, she likes the idea of him following her like a lemming. Richard's troubles are far from over, but this is a logical move for him.

Maggie: Jackson mentioned that he thought you two might be off but I had no idea. Richard: Catherine and I tend to keep our problems to ourselves. It was quite a show, huh?

Berea: I guess Im an outlier in that I dont find Catherine loathsome or frustrating. She loves Richard and Maggie as much as she loves Jackson. She very clearly wants Maggie back at Grey-Sloan because she is undoubtedly the best.

Her buying Pac-North is a complete boss move, and Im not mad at it.

This separation is getting messy, but I dont think shell close down the hospital. Richard is being petty and she tried to make amends, but he wanted to try and force her to apologize (which she does NOT need to do).

I find this interesting and am looking forward to seeing what will happen with Pac-North.

Big picture, I honestly sort of see it as a way for them to bring everyone back to Grey-Sloan, much like when Seattle Grace merged with Mercy West. No way were they going to keep the cast separated between the hospitals forever.

Jasmine: I hated it. If they call it quits, then so be it. I'm not that invested in them enough either way to care, but I'm confused with when they got to the point of being irreconcilable.

They've been on different pages for a bit. I hated Catherine's boss move. They have both done some messed up things in their relationship, and Richard expecting her to apologize when he was in the wrong is a whole other thing.

But buying Pac-North instead of letting him go was too petty for me. If the roles were reversed, I wouldn't hesitate to call it an abusive move.

The exertion of power, control, and financial flexing over a spouse in a relationship, regardless of the situation generally disturbs me.

Who was the MVP of the hour? What was your favorite scene and/or quote?

Meaghan: Levi is no doubt my MVP. Him meeting the love of his uncle's life and learning he and his uncle were more alike than he ever imagined was fantastic!

Paul: Levi, for sure. I was fascinated by the way Levi wanted to know more about his uncle's life, and how his lover was the one to reveal all the details.

Berea: My MVP is Maggie and all the shade that was thrown at dinner. You say actually a lot really cracked me up. I hadnt noticed, but he does!

Jasmine: Dean is my MVP. I have never related to him more than when he kept accidentally stirring up drama and sat there stuffing his face and watching all the drama and tension. It's me at every family gathering.

Saul loved men, he loved me for decades. But there was something inside of him that wouldn't let him. I would have married him. I would have built a life with him. But I couldn't allow myself to live a life with someone who hated himself for loving me.

I loved everything that involved Daniel, including him explaining how different the times were. It was something about him advising the younger generation in not just life, but life as a gay man that had a nice passing the torch sort of, "we put up with all of this so that you wouldn't have to" vibe; I found it touching.

Over to you Grey's Fanatics.

Hit the comments below with your responses. And if you missed it, watch Grey's Anatomy online to get caught up!

Grey's Anatomy airs Thursdays on ABC.

Edit Delete

Jasmine Blu is a senior staff writer for TV Fanatic. Follow her on Twitter.

More:
Grey's Anatomy Round Table: Levi Owns the Hour! - TV Fanatic

Med-Tech Innovation Awards 2020 finalists announced – Med-Tech Innovation

The finalists for the Med-Tech Innovation Awards 2020 have been announced,with a total of 23 entries shortlisted across five categories.

As part of the Medilink UK Healthcare Business Awards these finalists represent the pinnacle of their profession.

The winners will be announced at the annual sell-out gala dinner on 1st April at The Hilton Birmingham Metropole. The event will be hosted by medically qualified, critically acclaimed international stand-up comedian, Paul Sinha, with over 300 professionals from across the industry coming to celebrate with the winners, network with peers and share their pride in the industry.

This year saw some fantastic, inspiring entries recognising areas of innovation, outstanding achievement and ground-breaking success across the life science and healthcare technology sectors over the last year.

The categories and the nominations are:

3D PRINTING AWARD

Axial 3D - Axial 3D's surgical model service uses machine learning algorithms to aid in the conversion of patient scan data to 3D anatomical models, leading to reduced lead times.

ExpHand Prosthetics - ExpHand has developed affordable, expandable, customisable 3D printed prosthetics for children aged 3 to 10, with adjustable universal sockets that can be fitted at home by parents.

FabRx Ltd - The M3dimaker 3D printer prints solid oral medicine, enabling personalised doses of medicine to meet specific health and therapeutic requirements in a single pill.

MedScan 3D - MedScan 3D offers a 3D printed anatomical surgical model service, which uses expert adaption to produce anatomically accurate silicone test simulators for medical devices.

University of Liverpool - A digital electronic imaging system has been developed to enhance the quality control of the EBAM additive manufacturing process, to improve the reliability in the manufacture of bespoke orthopaedic implants.

CONNECTED HEALTH AWARD

Ainostics Ltd - Ainostics has developed an AI analysis engine which uses multi-modal patient data (scans, patient records, wearable sensors, etc) to perform highly accurate diagnosis and prognosis for early dementia.

FeelTect Tight Alright is a connected wearable device for measuring and monitoring sub-bandage pressure during compression therapy, reducing healing times and improving quality of life.

Game Doctor - Game Doctor have developed a healthcare analytics and education platform using mobile gaming, to map and predict health behaviours in patients and the public

The London Ambulance Service NHS Trust - An online Point of Care Testing (POCT) service for the London Ambulance Service (LAS) enables en-route pathological testing with results available online for the destination hospital - reducing patient treatment time and improving clinical outcomes.

Nemaura Medical Inc - SugarBEAT is a non-invasive continuous glucose monitor and lifestyle app for diabetes, providing a personalised and progressive behaviour change app to manage and prevent type 2 diabetes.

DESIGN AWARD

Nemera - Safe'n'spray is a smart drug delivery device, with a reusable child-resistant locking unit and fingerprint identifier, to monitor drug delivery and prevent overdosing.

Oxford VR - A virtual reality therapy platform with a computer-generated virtual coach for personalised treatment of phobias and mental health. Great success at clinical trial has led to adoption in four NHS trusts.

SleepAngel - This patented medical barrier bedding allows the bedding to breathe whilst being a 100% barrier to allergens and pathogens, reducing hospital-acquired infections and increasing sustainability in the hospital setting.

TheMoment - M-co is a non-invasive wearable device utilising pulsed cueing and focused vibrotactile stimulation to ease the symptoms of Parkinson's disease.

ENGINEERING AWARD

Biovation Orthopaedic Solutions - An instrument kit used to perform cartilage replacement implant surgery, for big toe arthritis, has been redesigned to eliminate pre-operative lead-times, reduce manufacturing costs and lead times as well as allow for more accurate surgery.

Carclo Technical Plastics - Specialist in-tool process control and monitoring equipment has been introduced to the injection moulding process of a drug delivery device to improve quality control and reduce inspection costs.

Emerson - Emerson have developed a micro solenoid valve for use in portable oxygen concentrators, which is light and compact with a significantly higher flow rate than competitor valves, enhancing the quality of life of the user.

Freudenberg Medical - Helix iMC technology continuously measures the inner geometry of silicone tubes during the extrusion process, to improve product quality and productivity as well as reducing waste and time to market.

Marsden - The Patient Transfer Scale is a transfer board with an in-built weighing scale to enable immobile and time-critical patients to be weighed instantly and accurately to allow for precise administering of drug doses and treatment.

MATERIALS INNOVATION AWARD

3M Medical Materials and Technologies - The 3M Extended Wear Medical Transfer Adhesives suite is a set of advanced solutions for stick-to-skin wearable devices which offer water resistance, breathability, elasticity and long wear times.

Paxxus - StreamOneR is an ultra-high barrier, hermetically sealable medical packaging solution designed for the number one polyester recycling stream, providing a higher performing and sustainable alternative to polypropylene medical packaging.

Spyras - Spyras have developed an affordable, disposable, paper-based wearable device for continuous real-time breathing analysis in hospitals. The device is designed to automatically alert clinicians of early signs of patient deterioration.

Stratasys - Specialist digital materials have been developed to allow the Stratasys Digital Anatomy Platform to replicate human anatomy which has the same biomechanical properties as native bone and tissue for realistic anatomical models.

Click here to get your tickets.

Go here to read the rest:
Med-Tech Innovation Awards 2020 finalists announced - Med-Tech Innovation

Greys Anatomy season 16: Will there be more Station 19 crossovers? Showrunner drops hint – Express.co.uk

This comes after episode 13 of Greys Anatomy featured a dinner party with Station 19s Dean Miller (Okieriete Onaodowan) asked to be come.

So far in both shows, the showrunner seems to have been using characters from both series interchangeabley in the episodes.

But, some fans of the show have been wondering whether this will keep happening across the two shows.

The crossovers partly began because Ben Warren (Jason Winston George), who is a Greys Anatomy doctor-turned Station 19 firefighter, appears in both shows.

Read more here:
Greys Anatomy season 16: Will there be more Station 19 crossovers? Showrunner drops hint - Express.co.uk

Khlo Kardashian warms the nets by exposing her sensual anatomy in a revealing dress – Play Crazy Game

The members ofthe Kardashian-Jenner clanhave made special efforts in recent times to show off their sculptural bodies,most supported by tiny intimate garments or bikinis, although they also show thata well-designed dresscan also be the perfect tool.

This is howKhlo Kardashiandecided to attend the exclusiveafter party of theOscarawardsorganized byBeyoncandJay Zwith a spectacular dress that leaves very little imagination while revealing thanks to its wide neckline and high side opening lots of skin of her well-turned body.

Honey! Im home!The socialite wrote to show off her fiery look while giving due credits tothose responsible for sending her so beautifulto the party along with her sistersKourtney and Kylie.Being the latterwell accompanied by her ex-partner and father of her daughter, Travis Scott, which has triggered several rumors of a possible reconciliation.

Khlos postcardhas exceeded two and a half million likes, which is in tune with the rest of the images shared this year in which she has endeavored to show off the figure that cost him so much work to build.

Tv specialist. Falls down a lot. Typical troublemaker. Hipster-friendly advocate. Food fan.

Read the original:
Khlo Kardashian warms the nets by exposing her sensual anatomy in a revealing dress - Play Crazy Game

Ex-Pfizer oncology R&D lead lands at Fierce 15 winner Vividion Therapeutics – FierceBiotech

Pfizers former longtime cancer research head Robert Abraham, Ph.D., has become the new chief scientific officer at a San Diego biotech after leaving the Big Pharma last year.

He moves over to 2017 Fierce 15 winner Vividion Therapeutics, a biotech looking to increase the number of proteins small molecules can target. Last April, it got off a $82 million series B financing round.

Its platform is based on the work of Benjamin Cravatt, Phil Baran and Jin-Quan Yu at the Scripps Research Institute and is designed to identify new sites in the proteomewhich is distinct in each cellthat can be drugged.

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Vividion spun out of Scripps back in 2017; its still pretty quiet on specifics of its pipeline, but it's looking to work on cancer and immunology through its selective small-molecule therapeutic platform.

RELATED: FierceBiotech's 2017 Fierce 15 | Vividion Therapeutics

Abraham will now help lead these efforts. Its a major get for the small biotech and will likely be a bit of a culture shock for Abraham, who joins Vividion from a 10-year tenure at Pfizer where he most recently served as senior vice president and group head, oncology R&D.

He "retired" from Pfizer last year, and was replaced by Calico's Jeff Settleman, Ph.D. last July.

We are delighted to have Bob join the Vividion family. His deep scientific expertise and experience managing a large and complex portfolio at Pfizer will help us successfully advance our broad and promising pipeline of selective small molecule programs, said Diego Miralles, CEO of Vividion.

Our proprietary platform has generated a diverse portfolio addressing several highly sought-after targets in the areas of oncology and immunology, and we look forward to leveraging Bob's insights as we create the small molecules of the future.

I am extremely excited to join the exceptionally talented and innovative team at Vividion," added Abraham.

The success the company has had in generating and progressing multiple compelling programs over such a short period of time is impressive. I look forward to helping Vividion realize the full potential of its technology platform to deliver highly differentiated, impactful medicines to patients.

Excerpt from:
Ex-Pfizer oncology R&D lead lands at Fierce 15 winner Vividion Therapeutics - FierceBiotech

Moms Role to Protect From Childhood Allergic Sensitization – Physician’s Weekly

For most children, immunoglobulin E (IgE) sensitization to food and respiratory allergens begins during the first few years of life. However, maternal allergen-specific immunoglobulin G (IgG) is transferred to offspring during pregnancy, thereby possibly averting the evolution of allergic sensitization. Using IgE reactivity profiles from asymptomatic children in early life, it is possible to predict both the likelihood of a child developing symptoms later in life and the severity of those symptoms.

Several factors are known or suspected to have an impact on allergic sensitization in children, both in terms of protection from, and facilitation of, IgE formation, says Christian Lupinek, MD. From allergen-specific immunotherapy (AIT), allergen specific IgG antibodies that block IgE binding to the respective allergen are known to be beneficial, as they can reduce symptom load in an allergen-specific manner when the patient is exposed to an allergen.

For a study published in the Journal of Allergy and Clinical Immunology, Dr. Lupinek and colleagues analyzed IgG reactivity to more than 160 microarrayed allergens in mothers during pregnancy, cord blood samples, breast milk, and infants in the first years of life (6 months, 12 months, and 5 years), exploring whether maternal allergen-specific IgG could protect offspring from IgE sensitization. The samples allowed studying both mother-to-child transferring of allergen-specific IgG and the subsequent production of allergen-specific antibodies in the infant.

Children with IgE-sensitization also have higher IgG levels to the same respective allergen, says Dr. Lupinek. This demonstrates an obviously high general propensity in allergic subjects to mount an antibody response to harmless environmental antigens.

The study showed a high correlation among allergen-specific IgG reactivity profiles in mothers, cord blood, and breast milk. Maternal allergen-specific IgG remained for some children at 6 months. The data clearly visualize the decline of the passively transferred maternal allergen-specific IgG, which are present at birth but hardly remain at 6 months of age, says Dr. Lupinek.

Compared with nonsensitized children, those who were IgE sensitized against an allergen at age 5 showed monumentally elevated allergen-specific IgG levels at the same age. By contrast, mothers with elevated levels of IgG antibodies against an allergen in their blood exceeding 30 ISU-G had children without allergic IgE sensitizations toward that particular allergena finding consistent for all 164 tested allergens. In comparison, only children of mothers with lower allergen-specific IgG antibodies had IgE sensitization to allergens. This implies that induction or passive transfer of allergen-specific IgG in pregnant women may facilitate prevention of allergic sensitization in their offspring, says Dr. Lupinek.

When examining allergens against which children at age 5 were sensitized, the study team observed that to most allergens, no mother had mounted an IgG-response that exceeded a level of 30 ISU-G (Table). According to Dr. Lupinek, This implies that both the spectrum and the level of allergen-specific IgG spontaneously formed in mothers would not be sufficient to convey protection from sensitization to their offspring.

The study produces significant evidence that throughout pregnancy, elevated maternal allergen-specific IgG levels protect offspring from allergic sensitization, potentially providing new solutions in the prevention of allergic diseases. The initial post-natal months appear to be a key period for allergic sensitization, as levels of maternal IgG antibodies transferred to the child are already low at 6 months. The observation that the passive transfer of allergen-specific IgG from mother to child may protect the child from getting sensitized to the respective allergens allows us to develop new strategies for the prevention of allergic sensitization says Dr. Lupinek.

Allergen-specific immunotherapy (via vaccination) and passive immunization with IgG isolated from subjects with elevated levels of allergen-specific IgG can both increase the number of protective IgG antibodies in the plasma of pregnant women. AIT treatment of pregnant women can avert offsprings development of IgE sensitization against correlating allergens. In this context, says Dr. Lupinek, it seems to be relevant for the treatment to be effective that IgG-levels exceed a particular threshold (ie, 30 ISU-G).

Lupinek C, Hochwallner H, Johansson C, et al. Maternal allergen-specific IgG might protect the child against allergic sensitization. J Allergy Clin Immunol. 2019;144(2):536-548. Available at https://www.jacionline.org/article/S0091-6749(19)30106-X/fulltext.

Read more here:
Moms Role to Protect From Childhood Allergic Sensitization - Physician's Weekly

‘We’re responding to this threat’: University of Alberta works to help stop novel coronavirus – Calgary Herald

The University of Albertas Li Ka Shing Institute of Virology says a drug once used in an Ebola outbreak could fight the novel coronavirus.

Remdesivir will be tested against the virus, known as 2019-nCoV, at the institute in Edmonton. Although there are regulatory hurdles related to getting samples of the coronavirus into the country, lab work has already begun, said D. Lorne Tyrrell, founding director of the Li Ka Shing Institute of Virology.

The prospects for developing an antivirus that can be used in patients is very good, and it may happen in the next few weeks and be readily available some compounds that are already on the market for their viruses that might work (against) this virus, said Tyrrell.

The institute is aiming to raise up to half a million dollars in funding, including rapid response grants from the Canadian Institute of Health Research, to go towards work on the novel coronavirus, Tyrrell said.

No one at the institute specializes in coronavirus at the moment. That is going to change very quickly, said Tom Hobman, professor of medical microbiology and immunology at the university, who noted that experts on coronaviruses have been recruited.

Since it can take years to get a brand new drug to market, researchers at the institute hope to find a drug thats already been developed to fight the virus.

Remdesivir, one of the drugs they will test, was used in the emergency treatment of patients with Ebola virus infection in the Democratic Republic of the Congo. The drug has shown activity in animal models against the viral pathogens MERS and SARS, which are coronaviruses that are structurally similar to the novel coronavirus, and has been used on a small number of patients.

Since the outbreak of the new coronavirus, it was just logical to ask whether this drug will work against the new coronavirus. The good thing was that its been tested, with tons of pre-clinical data, as well as in very difficult clinical settings, said Matthias Gtte, chair of the department of medical microbiology and immunology.

We are interested, always, not in the entire virus, but in the little machines the enzymes that help the virus to propagate. As soon as you shut down the machine, you shut down the virus, and you have a drug, said Gtte. Now, the goal is to see if the mechanism works the same way against the novel coronavirus.

If youre trying to respond very quickly to an outbreak, you dont really have the luxury of time to develop something completely new, said Dave Evans, professor of medical microbiology and immunology.

The challenge with all drug development is making sure it works and is safe, so its a common approach to test drugs that are known to be safe on new viruses, said Evans.

Viruses change, and new viruses are always emerging, said Tyrrell.

Public health efforts to contain the novel coronavirus have been more challenging than in other outbreaks, including SARS, but the mortality rate is so far much lower, he said. There have been at least 40,000 confirmed cases of the novel coronavirus worldwide, and 910 deaths, according to The World Health Organizations latest numbers.

(The institute) has been designed to look after major outbreaks in the world like this, and I just want you to know that were responding to this threat, said Tyrrell.

lijohnson@postmedia.com

twitter.com/reportrix

Visit link:
'We're responding to this threat': University of Alberta works to help stop novel coronavirus - Calgary Herald

Sihuan Pharmaceutical and Hetero Labs Limited Reached A Framework Cooperation Agreement in Pharmaceutical Manufacturing Area – Yahoo Finance

HONG KONG, Feb. 12, 2020 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd.(HKEX: 0460) ("Sihuan Pharmaceutical" or the "Company", together with its subsidiaries, the "Group") is pleased to announce that the Group and Hetero Labs Limited ("Hetero"), a company registered under the laws of India, reached a framework cooperation agreement (the "Cooperation") in the pharmaceutical manufacturing area after several rounds of discussion.

Under the terms of the framework cooperation agreement, the Cooperation includes research and development ("R&D"), product registration, technology transfer, raw materials supply and local manufacturing and commercialization of drugs in the fields of cardiovascular, cerebrovascular, neurology and anti-infectives including novel coronavirus (2019-nCoV), etc.

Backed by over 25 years of expertise in the pharmaceutical industry, Hetero is the world's leading producer of anti-retroviral drugs for the treatment of HIV/AIDS. Hetero caters about 40% of the identified HIV/AIDS patients globally through around 30 anti-retroviral products combinations. In addition, Hetero is growing as a reliable partner in the industry specializing in major therapeutic categories such as oncology, cardiovascular, neurology, hepatitis, nephrology, urology, diabetes, ophthalmology and immunology, etc., with around 300 products in the portfolio.

The signing of this framework cooperation agreement will achieve a win-win situation in which the two parties complement each other's strengths and jointly accelerate their development. On one hand, Hetero's anti-viral and anti-infection products will be introduced to China by Sihuan Phamaceutical which is equipped with standardized production capacity and strong marketing capabilities for local production and sales. This will also enrich the Group's R&D and product pipeline. On the other hand, Hetero will explore the great potential in the China market.

Dr. Che Fengsheng, Chairman and Executive Director of Sihuan Pharmaceutical said, "Based on the prevalence of the novel coronavirus infection pneumonia in China, both parties agreed to take the introduction, development and production of new coronavirus drugs as a priority issue, giving priority and contributing to China's fight against the pandemic ! "

-End -

About Hetero Labs Limited

Headquartered in Hyderabad, India, Hetero is one of India's leading generic pharmaceutical companies and one of the world's largest producers of anti-retroviral drugs for the treatment of HIV/AIDS. Backed by over 25 years of expertise in the pharmaceutical industry, Herero's strategic business areas spread across APIs, generics, biosimilars, custom pharmaceutical services and branded generics. Hetero is globally recognized for its strengths in research and development, manufacturing and commercialization of a wide range of products. Hetero caters about 40% of the identified HIV/AIDS patients globally through 30+ ARV products combinations . Hetero has 36 state-of-the-art manufacturing facilities strategically located worldwide, audited and approved by stringent regulatory authorities like U.S. FDA, EU, TGA-Australia, MCC-South Africa and others. Hetero is growing as leader and reliable partner of choice in the major therapeutic categories such as HIV/AIDS, oncology, cardiovascular, neurology, hepatitis, nephrology, urology, diabetes, ophthalmology, hepatology and immunology etc., with over 300 products in the portfolio.

About Sihuan Pharmaceutical Holdings Group Ltd.

Founded in 2001, Sihuan Pharmaceutical is a pharmaceutical group with 21 subsidiaries and integrated R&D, production and marketing and sales capabilities. Because of the continuing efforts over the past decade, Sihuan Pharmaceutical has formed a R&D platform with over 1,000 researchers conducting more than 110 pharmaceutical research projects currently. More than 300 patents on innovative drugs were granted in China and over 80 are PCT patents, covering pipeline projects including important areas of diabetes, oncology, anti-infectives and non-alcoholic steatohepatitis etc.

SOURCE Sihuan Pharmaceutical Holdings Group Ltd.

Here is the original post:
Sihuan Pharmaceutical and Hetero Labs Limited Reached A Framework Cooperation Agreement in Pharmaceutical Manufacturing Area - Yahoo Finance

Immune Therapeutics Inc. Provides Updates and Guidance on Reverse Stock Split and Name Change – Yahoo Finance

Awaiting completion of FINRA approval process

Orlando, Florida--(Newsfile Corp. - February 11, 2020) - Immune Therapeutics, Inc. (OTC Pink: IMUN) ("Immune" "IMUN" or the "Company"), a clinical late stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases today announced an update on the pending 1000 to 1 reverse stock split and name change of Immune Therapeutics.

Immune Therapeutics originally submitted the reverse and name request for a corporate action to FINRA and paid the applicable fees on November 27, 2019. Since then, the company has responded to FINRA's requests for further information multiple times, and we continue in our efforts to work diligently and cooperatively with FINRA to process the reverse and name change. Please note that the Company has no control of the FINRA approval process and as such the timing of any decisions our not in the Company's control.

Michael K. Handley, CEO of Immune, said, "We are disappointed in the delay in processing the reverse and name change and remain fully committed to the restructuring and success of IMUN. I would personally like to thank all of our shareholders for their patience in this process. We realize this delay has eroded share value, and confidence however, based on the extensive review by FINRA, we are optimistic that their approval could be given soon, at which time we will certainly inform shareholders immediately. Immune would like to thank our shareholders for standing behind us, as we continue to work in your interests with a commitment to the reverse and merger with Aletheia as soon as possible."

ABOUT Immune Therapeutics Inc.

Immune Therapeutics, Inc. is a late-stage biopharmaceutical company focused on the development and commercialization of highly innovative therapies for use in oncology, immunology and anti-inflammatory disease. Immune Therapeutics is actively developing T-cell activation immunotherapies in combination with other drug candidates to achieve immunomodulation in patients with cancer, auto-immune disease and inflammatory diseases.

FORWARD LOOKING STATEMENTS

This release may contain forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to, the possibility that some or all the matters and transactions considered by the Company may not proceed as contemplated, and by all other matters specified in the Company's filings with the Securities and Exchange Commission. These statements are made based upon current expectations that are subject to risk and uncertainty. The Company does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in the Company's filings with the Securities and Exchange Commission (www.sec.gov), including its recent periodic reports.

Contact:

Immune Therapeutics:Michael K. Handley(888) 613-8802 Ext. 100

http://www.immunetherapeutics.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/52312

More:
Immune Therapeutics Inc. Provides Updates and Guidance on Reverse Stock Split and Name Change - Yahoo Finance

IONpath Launches Research Services Offering Multiplexed Tissue Analysis to Empower Pharmaceutical Discovery and Development Programs – BioSpace

MENLO PARK, Calif., Feb. 11, 2020 /PRNewswire/ -- Ionpath Inc., today announces the launch of a dedicated service business providing access to their proprietary MIBIscope multiplexed imaging platform and its team of experts to support pharmaceutical and biotechnology companies working in immuno-oncology.

IONpath has previously provided custom research services to leading academic and pharmaceutical organizations as part of an Early Access Program. Now the company has formalized its intentions to become a partner of choice to those interrogating the tumor microenvironment to understand therapeutic mechanism of action and identify responder populations.

"We started this company because we love doing great science and working with great scientists," said Harris Fienberg, chief executive officer and co-founder, IONpath. "Our team is incredibly excited to enable the next generation of immunotherapy development on a massive scale."

Based in their global headquarters in Silicon Valley and serving clients from around the world, an expert team of engineers, pathologists and data scientists are leveraging the proprietary MIBIscope platform to help solve the most complex problems in immuno-oncology. The MIBIscope can simultaneously image forty or more individual proteins on a single slide with the reproducibility needed for large clinical studies. IONpath is building the capacity to stain, image and analyze over 15,000 highly multiplexed slides a year by the end of 2020. The company hopes to unlock valuable data about co-expression levels, proximity of cell populations and correlations to outcomes observed in patients to meaningfully contribute to the development of immunotherapies for partners across industry and academia.

If you or your company would be interested in learning more about what Research Services can do for your program, please contact us at research@ionpath.comto talk to our expert team or request a quote.

About IONpath, Inc.IONpath, Inc. is revolutionizing tissue imaging to accelerate medical discovery and improve human health. The company's MIBIscope System, which utilizes Multiplexed Ion Beam Imaging (MIBI) technology, represents a transformative step in tissue imaging by simultaneously multiplexing 40+ markers with single cell resolution. Leading research institutes and biotech and pharmaceutical companies are using the MIBIscope in immuno-oncology, immunology and neuroscience research where high-fidelity multiplexed imaging data is needed. In addition to the MIBIscope System IONpath empowers the research and development initiatives of academic, biotech and pharmaceutical partners through IONpath Research Services.

Visit http://www.ionpath.com to find out more.

Contact:Terri Hnatyszyn305-803-0824media@ionpath.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/ionpath-launches-research-services-offering-multiplexed-tissue-analysis-to-empower-pharmaceutical-discovery-and-development-programs-301003116.html

SOURCE IONpath, Inc.

Go here to see the original:
IONpath Launches Research Services Offering Multiplexed Tissue Analysis to Empower Pharmaceutical Discovery and Development Programs - BioSpace